CA-AGENDIA,-INC.
18.11.2020 13:02:29 CET | Business Wire | Press release
Agendia, Inc ., a world leader in precision oncology for breast cancer, and Paige , a global leader in AI-based digital diagnostics, today announced a first of its kind strategic partnership that will redefine precision oncology. The partnership will enable co-development of treatment planning tools that integrate the cloud-based Paige Platform with genomic information from Agendia’s proprietary MammaPrint® and BluePrint® diagnostic tests for patients with breast cancer. These new products will enable faster access to predictive and prognostic information along the entire continuum of care, from diagnosis and early intervention to metastatic treatment planning.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005250/en/
“Paige’s digital pathology platform is truly transformational for oncology and will catapult diagnostics forward as a whole. This partnership defines the democratization of treatment planning tools by accelerating access to these tests and the essential insights they provide for more patients globally,” said Mark Straley, Chief Executive Officer of Agendia. “Our goal is to provide same-day turnaround in most cases, enable earlier intervention, preserve limited biopsy or surgical tissue specimens, and extend key benefits to physicians and their patients with access to testing in countries where tissue ‘send out’ is not allowed. Whether a patient is in Manhattan or Mumbai, the ability to get real-time and accurate results from Agendia’s MammaPrint and BluePrint tests will improve how we are treating breast cancer today.”
The initial focus of the collaboration will be the development of digital tests for early treatment planning where genomic testing has played an essential role in determining recurrence risk and tumor biology as doctors and their patients make decisions about the path ahead. This can be especially important for patients with operable breast cancer. Beyond early intervention, AI-derived biomarkers will be used to augment genomic testing in the metastatic setting where a multitude of therapeutic options can add to the complexity of treatment planning.
“As the first company to receive FDA clearance, FDA breakthrough designation and two CE marks for digital and computational pathology products, Paige is delivering next-generation digital diagnostics that redefine how we approach cancer care,” said Leo Grady, Ph.D., Chief Executive Officer of Paige. “By combining our unique capabilities with Agendia’s leadership in breast cancer, we believe this innovative partnership can achieve our shared goal of transforming clear and actionable information into precision treatment for better patient outcomes. It will be the first of many AI-based diagnostic tests to come.”
For more information, please visit Agendia.com and Paige.ai.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
By developing evidence-based novel genomic tests and conducting groundbreaking research while building an arsenal of data that will help treat breast cancer, Agendia aims to improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc. and colleagues from Memorial Sloan Kettering Cancer Center (MSKCC). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA breakthrough designation for computational pathology products.
For additional information, please visit: https://www.Paige.ai , https://www.paigeplatform.com , Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201118005250/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AGC Pharma Chemicals Validates Facilities for CDMO Services via Scientist.com’s VERIF.i® Program1.7.2026 13:55:00 CEST | Press release
Scientist.com, the life sciences industry’s leading AI-enabled R&D orchestration platform and digital marketplace, and AGC Pharma Chemicals, a leading global Contract Development and Manufacturing Organization (CDMO) for small molecule API and HPAPI, announced today that AGC has successfully completed an onsite assessment of its new Barcelona facility using the VERIF.i® supplier pre-assessment program. The newly expanded Barcelona site strengthens AGC’s position as a global leader in the development and commercialization of complex small molecule Active Pharmaceutical Ingredients (APIs) and highly potent APIs (HPAPIs). Designed for maximum flexibility, safety, and energy efficiency, the facility expands AGC’s end-to-end capabilities from gram-scale to ton-scale production under the highest quality and sustainability standards. “At AGC Pharma Chemicals, we place the highest priority on the integrity of our operational processes and the expertise of our frontline teams,” said Jun Kurihar
Introducing Arbex: a New Global Leader in Tissue and Hygiene1.7.2026 13:37:00 CEST | Press release
$3.4 billion joint venture between Suzano and Kimberly-Clark launches independent operations and reveals key corporate details Upon launch, Arbex becomes one of the world’s largest tissue and hygiene businesses, operating across more than 70 markets on five continents, with its headquarters in the Netherlands and an operational office in London. The company will produce and sell leading global and regional brands including Kleenex®, Scott®, Cottonelle®, Andrex®, and Viva®, with 22 manufacturing sites in 14 countries. Ehab Abou-Oaf, previously President of International Family Care & Professional at Kimberly-Clark, will directly transition in as Arbex’s CEO, with the role to be based in the United Kingdom alongside the majority of the global executive team. Arbex, a new global leader in tissue and hygiene, today commences operations as an independent business and unveils details of its brand, leadership team, and company structure. Announced in June 2025 as a $3.4 billion joint venture
Klarna has received a favorable ruling in PriceRunner litigation, awarding damages of $1.97 billion1.7.2026 13:19:00 CEST | Press release
Klarna Group plc (NYSE: KLAR) today announces that the court has ruled in PriceRunner’s favor, awarding $1.97 billion in damages in an antitrust case brought by PriceRunner against Google. The award compensates for lost revenue caused by Google's preferential treatment of its own comparison-shopping service over independent price-comparison services, conduct that also drives up costs for consumers. "When markets work well, everyone benefits. Consumers get higher quality at lower cost, companies stay focused on serving customers rather than defending position, and society is better off for it. This ruling supports a healthier, more competitive market for the way people compare products and services — and that is good for everyone who shops," said Dan Greaves, Head of Communications and Policy, Klarna. Klarna acquired PriceRunner in 2022 to add rich product discovery, price comparisons, and product reviews to the Klarna app, and drive high-intent traffic to retail partners. Klarna has si
Objectway Acquires Swiss Private Banking Technology Business From FNZ to Strengthen Its Pan-European Positioning1.7.2026 13:10:00 CEST | Press release
The acquisition consolidates its pan-European footprint, by expanding in Switzerland and Liechtenstein, as well as creating opportunities to expand in other international wealth centres. The investment enhances Objectway’s core-to-digital banking capabilities and strengthens its end-to-end offering for private banks and their cross-border wealth business.Key takeaways Objectway strengthens its positioning in Switzerland and in key international cross-border wealth management hubs. The acquisition enhances Objectway’s end-to-end private banking proposition for mid-sized to large institutions, leveraging core banking expertise and scalable digital solutions. Objectway extends international operational footprint across Switzerland, Singapore and Tunisia, accelerating its growth strategy and reinforcing its ability to support banks facing cross-border expansion, consolidation, regulatory pressure and increasing operational complexity. Objectway, a global wealthtech partner for banking, wea
NIQ Completes Acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights Business, Expanding Digital Commerce Intelligence Capabilities1.7.2026 13:00:00 CEST | Press release
NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced that it has completed the acquisition of Flywheel’s China and Southeast Asia eCommerce Data & Insights business. The acquired business operates in China under the YiMian (“一面”) brand and is a leading provider of eCommerce, social commerce, and digital shelf solutions. The acquisition expands NIQ’s capabilities across China and Southeast Asia and strengthens its ability to measure and understand consumer behavior across retail, eCommerce, social commerce, and digital environments — advancing NIQ’s mission to deliver The Full View™, the most complete understanding of consumer behavior across online and offline channels. It also enhances NIQ’s data and analytics foundation by expanding access to rich digital commerce signals that support the development of more advanced analytics and AI-powered solutions. By bringing together NIQ’s global intelligence, analytics, and retail measurement capabilities with the ac
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom